Valuation dashboard for Alnylam Pharmaceuticals, Inc. (ALNY) with P/E 8.33, P/B 6.13, EV/EBITDA 17.3 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders.
Analysis Summary
Alnylam Pharmaceuticals, Inc. reported revenue of $3.71B in the most recent fiscal year, growing at a 5-year CAGR of 49.8%.
Trailing-twelve-month margins: gross margin 77.3%, operating margin 19.5%, net margin 54.3%.
At $165.00 (closing price, October 30, 2026), ALNY trades at a P/E of 8.33 and an ROE of 159.72%. Market capitalisation stands at $22.1B, placing it among large-cap names.
Balance sheet quality for ALNY: debt-to-equity ratio of 0.35, current ratio of 2.48 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 8.33 |
| Price / Book | 6.13 |
| EV / EBITDA | 17.3 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ALNY | Alnylam Pharmaceuticals, Inc. | $22.1B | 8.33 | 6.13 | 159.7% |
| IONS | Ionis Pharmaceuticals, Inc. | $7.2B | 16.37 | -110.8% | |
| ARWR | Arrowhead Pharmaceuticals, Inc. | $8.5B | 18.45 | -60.5% | |
| VRTX | Vertex Pharmaceuticals Incorporated | $141.7B | 32.53 | 7.01 | 23.3% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $134.0B | 30.25 | 6.57 | 23.3% |
| REGN | Regeneron Pharmaceuticals, Inc. | $95.5B | 20.50 | 2.82 | 15.1% |
| MRNA | Moderna, Inc. | $88.5B | 12.99 | -39.2% | |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $86.5B | 19.22 | 2.62 | 13.8% |
Price
| Price | $165.00 (closing price, October 30, 2026) |
| Market Cap | $22.1B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 159.72% |
| Return on Invested Capital | 15.42% |
| Return on Assets | 34.08% |
| Gross Margin | 77.28% |
| Operating Margin | 19.50% |
| Net Margin | 54.34% |
Related companies: IONS · ARWR · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX
Explore sector: Healthcare · Biotechnology
More sections of ALNY: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks